The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children

<h4>Objective</h4> <p>We aimed to characterise the effects of CYP2B6 polymorphisms, diurnal variation, and demographic factors on nevirapine pharmacokinetics in African children.</p> <h4>Methods</h4> <p>Nonlinear mixed-effects modelling conducted in NONMEM...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Bienczak, A, Cook, A, Wiesner, L, Mulenga, V, Kityo, C, Kekitiinwa, A, Walker, A, Owen, A, Gibb, D, Burger, D, McIlleron, H, Denti, P
Formato:	Journal article
Publicado em:	Oxford University Press 2016

Registros relacionados

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, A, et al.
Publicado em: (2016)

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
por: Bienczak, A, et al.
Publicado em: (2017)

Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
por: Bienczak, A, et al.
Publicado em: (2016)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
por: Oudijk, J, et al.
Publicado em: (2012)

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
por: L'homme, R, et al.
Publicado em: (2008)

Differential impact of nevirapine on artemether-lumefantrine pharmacokinetics in individuals stratified by CYP2B6 c.516G>T genotypes
por: Abdullahi, ST, et al.
Publicado em: (2020)

Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
por: Fillekes, Q, et al.
Publicado em: (2013)

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
por: Kikaire, B, et al.
Publicado em: (2007)

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial
por: Schomaker, M, et al.
Publicado em: (2024)

Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets.
por: Fillekes, Q, et al.
Publicado em: (2012)

Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
por: Burger, D, et al.
Publicado em: (2010)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
por: Mulenga, V, et al.
Publicado em: (2016)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
por: Kekitiinwa, A, et al.
Publicado em: (2017)

Virologic response to first-line efavirenz- or nevirapine-based anti-retroviral therapy in HIV-infected African children
por: Kekitiinwa, A, et al.
Publicado em: (2017)

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
por: Mulenga, V, et al.
Publicado em: (2010)

Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
por: Fillekes, Q, et al.
Publicado em: (2013)

The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
por: Musiime, V, et al.
Publicado em: (2014)

Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
por: Muro, E, et al.
Publicado em: (2012)

Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
por: Bogman, K., et al.
Publicado em: (2010)

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
por: Ellis, J, et al.
Publicado em: (2007)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
por: Byakika-Kibwika, P, et al.
Publicado em: (2012)

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
por: Musoke, P, et al.
Publicado em: (2015)

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
por: Pollock, L, et al.
Publicado em: (2009)

Population Pharmacokinetics Of Repaglinide In Healthy Subjects And Genetic Polymorphisms Of Cyp3a4 And Cyp2c8
por: Abu Bakar, Ruzilawati
Publicado em: (2008)

Population pharmacokinetics of artesunate and amodiaquine in African children.
por: Stepniewska, K, et al.
Publicado em: (2009)

CYP2B6*6 genotype specific differences in artemether‐lumefantrine disposition in healthy volunteers
por: Abdullahi, ST, et al.
Publicado em: (2019)

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
por: Gupta, R, et al.
Publicado em: (2010)

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
por: Kasirye, P, et al.
Publicado em: (2012)

DIURNAL AND SEMI-DIURNAL TEMPERATURE VARIABILITY OF THE MIDDLE ATMOSPHERE, AS OBSERVED BY ISAMS
por: Dudhia, A, et al.
Publicado em: (1993)

Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.
por: Prendergast, A, et al.
Publicado em: (2011)

Population pharmacokinetics of primaquine and its metabolites in African males
por: Chotsiri, P, et al.
Publicado em: (2024)

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis
por: Deshpande, D, et al.
Publicado em: (2018)

The impact of CYP3A4 and CYP3A5 polymorphisms on anastrozole's pharmacokinetics and pharmacodynamics in post-menopausal breast cancer patients
por: Abubakar, Murtala Bello
Publicado em: (2017)

Chloramphenicol pharmacokinetics in African children with severe malaria.
por: Kokwaro, G, et al.
Publicado em: (2006)

POPULATION PHARMACOKINETICS OF ARTESUNATE AND AMODIAQUINE IN AFRICAN CHILDREN
por: Stepniewska, K, et al.
Publicado em: (2008)

Neuropsychological function and diurnal variation in depression.
por: Porterfield, T, et al.
Publicado em: (1997)

Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis
por: Pei, Q, et al.
Publicado em: (2016)

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
por: Musiime, V, et al.
Publicado em: (2010)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
por: Munderi, P, et al.
Publicado em: (2010)

Pharmacokinetic-pharmacodynamic assessment of the safety of fexinidazole for the treatment of human African trypanosomiasis
por: Watson, J, et al.
Publicado em: (2018)